Department of Radiation Oncology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 3J1, Canada.
Curr Treat Options Oncol. 2023 Aug;24(8):988-1003. doi: 10.1007/s11864-023-01097-w. Epub 2023 May 22.
As more hospital-based proton treatment centres become operational, the indications for proton beam therapy (PBT) are being evaluated. Recent advances in PBT technology are expanding the indications for the use of protons in the treatment of central nervous system (CNS) tumours. Prospective trials that assess the late toxicity of different radiation therapy (RT) techniques are needed to confirm any expected reduction in long-term side effects with PBT. The ASTRO Model Policy on proton beam therapy currently supports the reasonable use of protons in the treatment of specific CNS tumour types. Specifically, PBT plays a key role in the management of CNS tumours where anatomy, extent of disease or previous treatment cannot be satisfactorily addressed with conventional RT. As the availability of PBT rises around the world, the number of patients with CNS disease treated with PBT will continue to grow.
随着越来越多的医院质子治疗中心开始运营，质子束治疗（PBT）的适应证正在得到评估。PBT 技术的最新进展正在扩大质子在治疗中枢神经系统（CNS）肿瘤中的应用指征。需要前瞻性试验来评估不同放射治疗（RT）技术的晚期毒性，以确认 PBT 是否能降低长期副作用。ASTRO 质子束治疗模型政策目前支持在治疗特定 CNS 肿瘤类型中合理使用质子。具体来说，PBT 在不能用常规 RT 充分解决解剖结构、疾病范围或既往治疗问题的 CNS 肿瘤的治疗中起着关键作用。随着 PBT 在全球的普及，用 PBT 治疗的 CNS 疾病患者数量将继续增加。
